Answers are grounded in this paper and cite their sources.
Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo. (Funded by Janssen Research and Development; SPARTAN ClinicalTrials.gov number, NCT01946204 .).
No takes yet. Share an insight, caveat, or question.
Smith et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: